GlassScriptPhysician profile
Mohammad Munir Zaitoon
NPI 1659378222
$2,335.00
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $386 · 2020: $213 · 2021: $522 · 2022: $487 · 2023: $543 · 2024: $184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $727.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $726.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,170.41 | 2019-2024 | Xtandi, Myrbetriq |
| Pfizer INC. | $464.05 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $150.52 | 2023-2024 | Gemtesa, Orgovyx |
| Bayer Healthcare Pharmaceuticals INC. | $75.81 | 2022-2024 | |
| Tolmar Pharmaceuticals, INC. | $70.34 | 2021 | |
| Merck Sharp & Dohme LLC | $63.08 | 2020-2023 | Keytruda |
| Urovant Sciences INC | $51.69 | 2021-2022 | |
| Abbvie INC. | $47.18 | 2021-2023 | Lupron Depot |
| Ferring Pharmaceuticals INC. | $43.98 | 2019 | |
| Dendreon Pharmaceuticals LLC | $34.81 | 2023-2024 | Provenge |
| Accord Healthcare, INC. | $24.80 | 2022 | |
| Myovant Sciences INC. | $23.18 | 2021 | |
| Coloplast Corp | $20.84 | 2023 | Speedicath |
| Tolmar, INC. | $17.06 | 2023 | |
| 180 Medical, INC. | $15.52 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Clarus Therapeutics INC. | $14.00 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $12.91 | 2019 | |
| Convatec INC. | $11.84 | 2021 | |
| Janssen Biotech, INC. | $11.78 | 2022 | |
| Urogen Pharma, INC. | $11.20 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$986.22 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Zaitoon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.